Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10314030 | 0.85 | ALDH1A1 (0.45) | TTRCA12CA1CA2CA7 | |
| SCHEMBL10313842 | 0.85 | ALDH1A1 (0.45) | TTRCA12CA1CA2CA7 | |
| SCHEMBL31168657 | 0.84 | TTR (0.45) | KDM4EKMT2ASMN1; SMN2MEN1TTR | |
| SCHEMBL4132779 | 0.81 | PLAU (0.51) | KDM4ESMN1; SMN2PLAUALDH1A1LMNA | |
| SCHEMBL4132784 | 0.81 | PLAU (0.51) | KDM4ESMN1; SMN2PLAUALDH1A1LMNA | |
| SCHEMBL16125101 | 0.77 | KMT2A (0.41) | KDM4EKMT2ASMN1; SMN2MEN1TTR | |
| SCHEMBL14901131 | 0.77 | KMT2A (0.41) | KDM4EKMT2ASMN1; SMN2MEN1TTR | |
| SCHEMBL15204346 | 0.73 | KDM4E (0.43) | KDM4EKMT2ASMN1; SMN2MEN1TTR | |
| SCHEMBL3179944 | 0.73 | ABL1 (0.51) | KDM4EKMT2ASMN1; SMN2MEN1ABL1 | |
| SCHEMBL15204344 | 0.73 | KDM4E (0.43) | KDM4EKMT2ASMN1; SMN2MEN1TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493459-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493459-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2016-06-23 | — | — | US | disclosed |
| US-9303028-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303028-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20140148435-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148435-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8691986-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691986-B2 | Azetidine and piperidine compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2014-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176874-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE2A | KDM4E 750/4885KMT2A 1216/4885SMN1; SMN2 2366/4885 |
| US-20140148435-A1 | AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE9A, PDE2A | KDM4E 750/4885KMT2A 1216/4885SMN1; SMN2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.